DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL

Phase 2

Recruiting

Conditions: Clpd-Nk
T-LGL Leukemia

Interventions: Drug: thalidomide + prednisone + methotrexate

First Posted Date: 2020-07-01

Last Posted Date: 2020-07-01

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 42

Registration Number: NCT04453345

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Tongji hopital, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 6 locations

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Phase 2

Completed

Conditions: Acquired Pure Red Cell Aplasia

Interventions: Drug: bortezomib/dexamethasone

First Posted Date: 2020-06-09

Last Posted Date: 2024-11-18

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 18

Registration Number: NCT04423367

Locations: 🇨🇳
The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China
🇨🇳
Regenerative Medicine Center, Tianjin, China
🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Phase 2

Recruiting

Conditions: Refractory/Relapsed Autoimmune Hemolytic Anemia

Interventions: Drug: Ibrutinib

First Posted Date: 2020-05-21

Last Posted Date: 2024-02-12

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 18

Registration Number: NCT04398459

Locations: 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳
The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China
🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

Not Applicable

Active, not recruiting

Conditions: Transfusion Dependent Beta-Thalassaemia

Interventions: Biological: ET-01

First Posted Date: 2020-05-18

Last Posted Date: 2023-11-27

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3

Registration Number: NCT04390971

Locations: 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Phase 1

Conditions: Multiple Myeloma

Interventions: Drug: C-CAR088

First Posted Date: 2020-03-26

Last Posted Date: 2020-03-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 10

Registration Number: NCT04322292

Locations: 🇨🇳
InstituteHBDH, TianJin, China

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: C-CAR066

First Posted Date: 2020-03-20

Last Posted Date: 2023-07-19

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 7

Registration Number: NCT04316624

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Phase 2

Recruiting

Conditions: Essential Thrombocytopenia

Interventions: Drug: Recombinant Interferon Alpha
Drug: Pegylated interferon alfa-2b

First Posted Date: 2020-01-13

Last Posted Date: 2024-07-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 40

Registration Number: NCT04226950

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Gene Therapy for Chinese Hemophilia B

Not Applicable

Completed

Conditions: Hemophilia B

Interventions: Genetic: Single dose intravenous injection of BBM-H901

First Posted Date: 2019-10-22

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 10

Registration Number: NCT04135300

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Phase 1

Conditions: Transformed Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma

Interventions: Biological: BZ019

First Posted Date: 2019-08-26

Last Posted Date: 2020-03-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 12

Registration Number: NCT04067414

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Early Phase 1

Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Interventions: Biological: CD19-CD22 CAR-T cells

First Posted Date: 2019-07-26

Last Posted Date: 2022-08-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 2

Registration Number: NCT04034446

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy